跳至主要内容
临床试验/CTRI/2020/01/022727
CTRI/2020/01/022727已完成4 期

A pilot study for breast cancer screening by clinical breast examination (CBE) and iBreastExam (iBE) for early detection of breast cancer

Prayas1 个研究点 分布在 1 个国家目标入组 4,000 人开始时间: 2020年1月15日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
4,000
试验地点
1
主要终点
1. The outcome will be women detected with breast cancer correctly by clinical breast examination and iBreastExam

研究概览

简要总结

Breast cancer is the most common cancer among women in India. Mammography screening is the mainstay of breast cancer screening in the developed / high-income countries however such organized screening programmes are extremely difficult/ expensive to implement in the low- and middle-income countries. Hence alternative screening strategies must be evaluated.    iBreastExam is a new technology that is approved by the USFDA and is approved in India. According to the World Health Organization (WHO), screening programmes should be undertaken only when their effectiveness has been demonstrated, when resources are sufficient to cover nearly all of the target group, when facilities exist for follow-up of those with abnormal results to confirm diagnoses and ensure treatment and when prevalence of the disease is high enough to justify the effort and costs of screening. We are proposing a study to evaluate the diagnostic performance characteristics of  Clinical Breast Examination (CBE)  and iBreastExam for the early detection of breast cancer. Previous studies have been conducted in hospital settings and among women visiting the hospital/ breast clinic. Our study will be conducted in a community setting and women who test positive by either CBE or iBreastExam will be referred to an Expert Breast Surgeon. Those who are detected as being normal / negative by the breast surgeon will be assured and will be sent back. Women who have a lump detected by the breast surgeon on CBE will undergo triple diagnostic tests including FNAC for the final diagnosis.

研究设计

研究类型
Interventional
分配方式
Not Applicable
盲法
Not Applicable

入排标准

年龄范围
40.00 Year(s) 至 69.00 Year(s)(—)
性别
Female

入选标准

  • Consenting women.

排除标准

  • Women who have undergone breast surgery.

结局指标

主要结局

1. The outcome will be women detected with breast cancer correctly by clinical breast examination and iBreastExam

时间窗: single

2. Test performance of clinical breast exam and iBreastExam in detecting breast cancer

时间窗: single

次要结局

  • To study the test performance of CBE and iBreastExam in detecting lumps with histopathology as the reference standard

研究者

发起方
Prayas
申办方类型
Other [non-profit organization]

研究点 (1)

Loading locations...

相似试验